| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 20 May 2024 | 13 May 2024 |
| JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2024 inter alia to consider and approve the Audited Financial Result of the company for the quarter and year ended March 31 2024 and recommendation of dividend if any for the financial year ended March 31 2024. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited (Standalone) Financial Results for the quarter and year ended March 31, 2024. In this regard, kindly find enclosed the following: 1.Audited (Standalone) Financial Results along with Independent Auditors Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2024. 2. The Board recommended a dividend of Rs. 5/- (100%) per equity share for the financial year ended March 31, 2024. (As Per BSE Announcement dated on 20.05.2024) | ||
| Board Meeting | 2 Feb 2024 | 25 Jan 2024 |
| JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2024 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2023. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2023. In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report by the Statutory Auditors of the Company for the quarter and nine months ended December 31, 2023. The Board Meeting commenced at 04:15 p.m. and concluded at 05:05 p.m. Please find enclosed the intimation on change in Key Managerial Personnel. (As Per BSE Announcement dated on 02.02.2024) | ||
| Board Meeting | 3 Nov 2023 | 26 Oct 2023 |
| JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of Jagsonpal Pharmaceuticals Limited (the Company) is scheduled to be held on Friday November 03 2023 to consider and approve inter-alia the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2023 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter and half year ended September 30, 2023. In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report by the Statutory Auditors of the Company for the quarter and half year ended September 30, 2023. The Board Meeting commenced at 12:45 p.m. and concluded at 13:40 p.m. Please enclose herewith quarterly and half yearly financial results with limited review report for the quarter and half year ended on September 30, 2023. Board of Director at its meeting held today, inter alia considered and approved in principle divestment of Companys Faridabad facility. (As per BSE Announcement Dated on 03/11/2023) | ||
| Board Meeting | 2 Aug 2023 | 25 Jul 2023 |
| JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of Jagsonpal Pharmaceuticals Limited (the Company) is scheduled to be held on Wednesday August 02 2023 to consider and approve inter-alia the Unaudited Financial Results of the Company for the quarter ended June 30 2023. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter ended June 30, 2023. In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report by the Statutory Auditors of the Company for the quarter ended June 30, 2023. Kindly find enclosed the Unaudited Financial Results for the quarter ended June 30, 2023 along with Limited Review Report (As per BSE Announcement Dated on 02/08/2023) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
